SynthesisBlood2017
Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.
Synthesis in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Comorbidity Burden and Prognosis in Patients Aged 80+ Years With Large B-Cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2026Article
- Updates of CSCO guidelines for diagnosis and treatment of lymphoma: 2026 edition.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure.Leukemia & lymphoma · 2025Article
- Review
- Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma.JACC. CardioOncology · 2024Article
- Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials.Leukemia & lymphoma · 2024Review
- Hodgkin lymphoma treatment for older persons in the modern era.Hematology. American Society of Hematology. Education Program · 2023Article
- The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy.Haematologica · 2023Article
- Reduced-Intensity Anthracycline-Free Chemoimmunotherapy in Elderly Patients With Newly Diagnosed or Relapsed Diffuse Large B-Cell Lymphoma.Journal of hematology · 2023Article
- Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years' real-world experience in a single institute.Annals of hematology · 2023Article
- Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.Annals of hematology · 2023Article
- Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.Haematologica · 2022Article
- A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China.Frontiers in pharmacology · 2022Article
- A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.Blood advances · 2021Article
- The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.Cancer medicine · 2021Article
- Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.Blood advances · 2021Article
- Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives.Journal of clinical medicine · 2021Review
- Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in Older Adults with Diffuse Large B-Cell Lymphoma.The oncologist · 2021Article
- Approaches to aggressive B-cell lymphomas in less fit patients.Hematology. American Society of Hematology. Education Program · 2020Review
- Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches.Current oncology reports · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Survival outcome for elderly patients with newly diagnosed diffuse large B-cell lymphoma remains suboptimal in the rituximab era. In this systematic review, we summarize available evidence relevant to the inclusion of anthracycline in upfront chemoimmunotherapy for these elderly patients and highlight the need of prospective clinical trials. With limited prospective data, we find that pretreatment comprehensive geriatric assessment accurately predicts survival and treatment-related toxicities, suggesting its potential role in guiding overall treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.